Top Piper Sandler analyst Yasmeen Rahimi said the firm’s recent Healthcare Conference gave her stronger confidence in several biotech names heading into 2026. She said the updates from management teams offered a clearer view of upcoming launches and possible approvals.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
It is worth noting that Rahimi ranks 314 out of more than 10,000 analysts tracked by TipRanks. She has a success rate of 46%, with an average return per rating of 25% over a one-year timeframe.
The 5-star analyst pointed to four commercial-stage companies she continues to back: Crinetics Pharmaceuticals (CRNX), Cytokinetics (CYTK), Madrigal Pharmaceuticals (MDGL), and Soleno Therapeutics (SLNO). She believes each company has a solid plan for its drug rollout and expects these launches to gain momentum next year.
She also highlighted a group of companies that may see approvals in 2026, including Namsen Pharma (NAMS), Praxis Precision Medicines (PRAX), Savara (SVRA), and Unicycive Therapeutics (UNCY). Rahimi said the data behind these programs is strong and supports a high chance of approval.
Rahimi believes 2026 could be a constructive year for the biotech sector, with a mix of ongoing launches and important regulatory decisions ahead.
Which Stock Is Best to Buy Now?
We used the TipRanks Stock Comparison tool to see how Wall Street analysts rate Crinetics Pharmaceuticals, Cytokinetics, Madrigal, and Soleno Therapeutics — and to compare which of these biotech stocks currently offers the strongest upside.
